Log In
Print
BCIQ
Print
Print this Print this
 

SIRPalphaFc (formerly TTI-621)

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionSignal regulatory protein alpha (SIRPA) fused to immunoglobulin Fc region, which acts as a soluble decoy receptor to block CD47
Molecular Target CD47
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.9M

$1.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today